Stanford Cancer Center is offering new hope to melanoma patients through a groundbreaking cellular therapy called tumor infiltrating lymphocyte (TIL) therapy. This is the first approved cellular therapy for solid tumors, marking a significant advancement. TIL therapy involves expanding a patient’s immune cells to target and destroy cancer. In clinical trials, 31% of patients saw their tumors shrink or disappear, with 40% remaining treatment-free after 18 months. This one-time treatment is designed for patients with advanced melanoma who have exhausted other options, providing a much-needed alternative to clinical trials or hospice care.